Novel lactobacillus reuteri atg-f4 strain having function of enhancing dopamine secretion and pharmaceutical composition comprising same for prevention or treatment of psychopathy

Abstract

A Lactobacillus reuteri ATG-F4 strain (Accession number KCTC13717BP) is proposed. The strain has the function of enhancing dopamine secretion, and thus can be used as a pharmaceutical composition or a functional health food for the prevention or amelioration of mental illnesses, such as memory disorder, depressive disorder, generalized anxiety disorder, bipolar disorder, and the like, as well as Parkinson's disease, or can be used as a very effective composition for the improvement of memory or cognitive function. Moreover, the strain exhibits anti-inflammatory efficacy of upregulating the expression of IL-10 (interleukin-10) and inhibiting the generation of nitric oxide (NO) and is not resistant to antibiotics, and can thus be readily applied to a variety of foods having health improvement effects.

Dependencies are inferred from the claim text.